Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus)

Blood

Volumn 116, Issue 12, 2010, Pages 2005-2010

  Feys, Hendrik B ^a   Roodt, Jan ^b,c   Vandeputte, Nele ^a   Pareyn, Inge ^a   Lamprecht, Seb ^b   Van Rensburg, Walter J ^b   Anderson, Patricia J ^d   Budde, Ulrich ^e   Louw, Vernon J ^b   Badenhorst, Philip N ^b,c   Deckmyn, Hans ^a   Vanhoorelbeke, Karen ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF THE FREE STATE   (South Africa)

^c Universitas Private Hospital   (South Africa)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Coagulation Laboratory   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPLENIA; BABOON; CONTROLLED STUDY; DISEASE MODEL; HEART MUSCLE ISCHEMIA; HEMOLYTIC ANEMIA; IMMUNOHISTOCHEMISTRY; MICROANGIOPATHY; MICROTHROMBUS; NONHUMAN; PAPIO URSINUS; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; PATHOLOGY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOSIS; TIME; TISSUE DISTRIBUTION;

ADAM PROTEINS; ANIMALS; ANTIBODIES, MONOCLONAL; ENZYME INHIBITORS; PAPIO; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOSIS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 77957195023     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-280479     Document Type: Article

References (51)

1. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982; 307(23):1432-1435.
2. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood. 2002;99(11):3971-3977.
3. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494. (Pubitemid 32938741)
4. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol. 2008;3: 249-277.
5. Moake JL. Thrombotic thrombocytopenic purpura: the systemic clumping "plague." Annu Rev Med. 2002;53:75-88.
6. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000;96(4):1223-1229.
7. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339(22):1585-1594.
8. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma-exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325(6): 393-397.
9. Howard MA, Williams LA, Terrell DR, et al. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: III. An additional study of 57 consecutive patients, 2002-2005. Transfusion. 2006;46(1):154-156.
10. Nguyen L, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura: IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion. 2009;49(2): 392-394.
11. Hovinga JAK, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-1511.
12. Mayr FB, Knobl P, Jilma B, et al. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion. 2010;50(5):1079-1087.
13. Chauhan AK, Motto DG, Lamb CB, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006;203(3):767-776.
14. Banno F, Kokame K, Okuda T, et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006;107(8):3161-3166.
15. Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115(10):2752-2761. (Pubitemid 41434402)
16. Fujimura Y, Matsumoto M, Kokame K, et al. Pregnancy- induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol. 2009;144(5):742-754.
17. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2003; 10(5):339-344. (Pubitemid 36936604)
18. Cserti CM, Landaw S, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura? J Clin Apher. 2007; 22(1):21-25.
19. Naqvi TA, Baumann MA, Chang JC. Postoperative thrombotic thrombocytopenic purpura: a review. Int J Clin Pract. 2004;58(2):169-172. (Pubitemid 38425747)
20. Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010;31(1):11-19.
21. Matsumoto M, Kokame K, Soejima K, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood. 2004;103(4):1305-1310. (Pubitemid 38168641)
22. Schneppenheim R, Budde U, Oyen F, et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood. 2003;101(5):1845-1850. (Pubitemid 36237583)
23. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495-497.
24. Anderson PJ, Kokame K, Sadler JE. Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem. 2006;281(2):850-857.
25. Feys HB, Liu F, Dong N, et al. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost. 2006;4(5):955-962.
26. Wu D, Vanhoorelbeke K, Cauwenberghs N, et al. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood. 2002;99(10):3623-3628. (Pubitemid 34534531)
27. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100. (Pubitemid 40524057)
28. Feys HB, Canciani MT, Peyvandi F, et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007;138(4):534-540. (Pubitemid 47063038)
29. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher. 1998;13(1):16-19. (Pubitemid 28215135)
30. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature. Medicine. 1981;60(6):413-428. (Pubitemid 12207235)
31. Hughes C, Mcewan JR, Longair I, et al. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost. 2009;7(4):529-536.
32. Raife TJ, Cao WJ, Atkinson BS, et al. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood. 2009; 114(8):1666-1674.
33. Desch KC, Motto DG. Thrombotic thrombocytopenic purpura in humans and mice. Arterioscler Thromb Vasc Biol. 2007;27(9):1901-1908. (Pubitemid 47312297)
34. Peyvandi F, Palla R, Lotta LA, et al. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(4):631-640.
35. Camilleri RS, Cohen H, Mackie IJ, et al. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost. 2008; 6(2):331-338.
36. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001;14(2):437-454.
37. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93(2):232-239. (Pubitemid 351397711)
38. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103(11):4043-4049.
39. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood. 2007;109(7): 2815-2822. (Pubitemid 46482076)
40. Bohm M, Betz C, Miesbach W, et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol. 2005;129(5):644-652. (Pubitemid 40825826)
41. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A. 2002;99(18):11902-11907. (Pubitemid 34994496)
42. Plaimauer B, Fuhrmann J, Mohr G, et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood. 2006; 107(1):118-125. (Pubitemid 43053532)
43. Savasan S, Taub JW, Buck S, et al. Congenital microangiopathic hemolytic anemia and thrombocytopenia with unusually large von Willebrand factor multimers and von Willebrand factor-cleaving protease. J Pediatr Hematol Oncol. 2001;23(6):364-367.
44. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002; 100(2):710-713. (Pubitemid 34761143)
45. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11-18.
46. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of literature. Medicine. 1966;45(2):139.
47. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor-VIII related antigen. Thromb Res. 1985;38(5):469-479. (Pubitemid 15041946)
48. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities: a review of 56 autopsy cases. Arch Pathol Lab Med. 2003;127(7):834-839.
49. Schneppenheim R, Hovinga JAK, Becker J, et al. A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost. 2006;96(1):3-6. (Pubitemid 44160863)
50. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354(18):1927-1935.
51. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003; 102(1):60-68. (Pubitemid 36759636)